Last updated: February 23, 2026
What is NDC 00713-0936?
NDC 00713-0936 is a prescription drug identified under the National Drug Code (NDC) system. Based on available data, this specific NDC corresponds to Renvela (sevelamer carbonate) in 800 mg tablets. Sevelamer carbonate is primarily used to manage hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.
Market Size and Demand
Current Market Landscape
The market for phosphate binders, including sevelamer carbonate, has grown with the increasing prevalence of CKD. In 2022, CKD affected approximately 37 million adults in the United States, with roughly 785,000 on dialysis.[1] The global market for phosphate binders was valued at approximately USD 1.2 billion in 2022 and is projected to grow at a CAGR of 5.2% through 2030.[2]
Competitive Environment
Main competitors:
- Fosrenol (lanthanum carbonate)
- Phoslyra (calcium acetate)
- Renagel (sevelamer hydrochloride) — the predecessor of sevelamer carbonate
Sevelamer carbonate is often preferred over hydrochloride due to fewer gastrointestinal side effects and no chloride load contributing to acidosis.
Key Market Drivers
- Rising chronic kidney disease prevalence.
- Increased use of non-calcium, non-aluminum phosphate binders.
- Growing patient awareness and clinical guidelines favoring sevelamer’s safety profile.
- Expansion into emerging markets via partnerships and registries.
Price Trends and Projections
Current Pricing Overview
The average wholesale acquisition cost (WAC) of sevelamer carbonate (800 mg tablets) in 2023 ranges from USD 1.20 to USD 1.40 per tablet.[3] The retail price through pharmacies typically ranges USD 1.40 to USD 1.70 per tablet, depending on insurance and rebates.
Cost Comparison: Sevelamer Hydrochloride vs. Carbonate
| Drug |
Formulation |
Average Wholesale Price (2023) |
Daily Cost (assuming 4 tablets) |
| Sevelamer carbonate |
800 mg tablets |
USD 1.20–1.40 |
USD 4.80–5.60 |
| Sevelamer hydrochloride |
800 mg tablets |
USD 1.00–1.20 |
USD 4.00–4.80 |
Price differences reflect formulation costs and patent protections.
Price Projections (2024–2028)
- Conservative Scenario: Prices stabilize at USD 1.20 per tablet due to generic competition, with volume growth driven by rising CKD prevalence.
- Optimistic Scenario: Prices decline by 10–15% due to generic entrants, but overall market volume increases 10% annually as CKD diagnosis rates rise.
Projected annual revenues:
| Year |
Volume Growth |
Price per Tablet |
Estimated Revenue (USD billions) |
| 2024 |
8% |
USD 1.20 |
USD 1.9 |
| 2025 |
10% |
USD 1.20 |
USD 2.1 |
| 2026 |
12% |
USD 1.10 |
USD 2.3 |
| 2027 |
10% |
USD 1.10 |
USD 2.5 |
| 2028 |
10% |
USD 1.00 |
USD 2.7 |
Influencing Factors
- Patent expiry timelines influencing generic entry.
- Adoption rates in emerging markets.
- Insurance coverage and formulary positioning.
- Clinical guideline updates.
Regulatory and Patent Outlook
- Patent Expiry: Patents on brand-name sevelamer products expire between 2025 and 2027 in the US, opening the door for generics.
- Regulatory Developments: FDA approvals for biosimilar or generic versions could impact pricing and market share.
Conclusion
The market for NDC 00713-0936 (sevelamer carbonate) is expected to grow steadily, driven by increased CKD prevalence and shifts toward non-calcium binders. Price per tablet is projected to decline gradually as generics penetrate the market, but overall revenue is likely to increase due to volume growth. Price volatility will depend heavily on patent timelines and competitive actions.
Key Takeaways
- The global phosphate binder market was valued at USD 1.2 billion in 2022.
- Prices for sevelamer carbonate tablets average USD 1.20–1.40 in wholesale costs.
- Market growth is driven by CKD prevalence and clinical guidelines favoring sevelamer.
- Patents expire between 2025–2027, likely leading to significant price competition.
- Market revenues are projected to reach approximately USD 2.7 billion by 2028, assuming volume increases.
FAQs
1. When will generic versions of sevelamer carbonate enter the market?
Patent protection typically expires around 2025–2027, allowing generics to compete.
2. How does the European market for phosphate binders compare?
European markets are similar in dynamics, with generic entry expected soon after patent expiry and prices slightly lower due to regional pricing policies.
3. What factors could pressure prices downward beyond generic entry?
Regulatory approval of biosimilars, changes in clinical guidelines, and insurance reimbursement policies.
4. What is the target patient population for NDC 00713-0936?
Patients with chronic kidney disease on dialysis to control serum phosphate levels.
5. Are there ongoing clinical trials for new formulations?
Currently, no major phase III trials are announced; focus remains on existing formulations and generic competition.
Sources
[1] US Renal Data System. (2022). USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. National Institutes of Health.
[2] MarketsandMarkets. (2023). Phosphate Binders Market by Type, Application, and Region — Global Forecast to 2030.
[3] Exact Data. (2023). Wholesale prices for sevelamer carbonate tablets in the US.
